No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
HK Stock MarketDetailed Quotes
03692 HANSOH PHARMA
- 15.380
- -0.280-1.79%
Market Closed Apr 19 16:08 CST
91.29BMarket Cap25.25P/E (TTM)
15.600High14.960Low6.89MVolume15.600Open15.660Pre Close105.24MTurnover0.12%Turnover Ratio25.25P/E (Static)5.94BShares17.24052wk High3.21P/B91.29BFloat Cap9.33952wk Low0.12Dividend TTM5.94BShs Float46.362Historical High0.100Dividend LFY4.09%Amplitude9.339Historical Low15.269Avg Price2000Lot Size0.79%Div YieldTTM0.65%Div Yield LFY
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Hanson Pharmaceuticals (03692.HK) to issue 2.3 million shares under restricted share unit plans
On April 19, GLONGHUI | Hanson Pharmaceuticals (03692.HK) announced that it will issue 2.3 million shares of the company on April 19, 2024 in accordance with the restricted share unit plan approved and adopted by the company on May 27, 2019.
Is Hansoh Pharmaceutical Group Company Limited (HKG:3692) Trading At A 23% Discount?
Key Insights The projected fair value for Hansoh Pharmaceutical Group is HK$20.45 based on 2 Stage Free Cash Flow to Equity Hansoh Pharmaceutical Group's HK$15.66 share price signals that it might b
Hansoh Pharmaceutical Secures Chinese Nod for Trial of Anti-Cancer Drug
Hansoh Pharmaceutical Group (HKG:3692) said Chinese regulator NMPA has granted clinical trial approval for the group's HS10504 tablets, being developed to treat advanced, non-small-cell lung cancer, according to a Wednesday filing with the Hong Kong bourse.
Hanson Pharmaceuticals (03692.HK): HS-10504 tablets received clinical trial notice
Gelonghui, April 3 | Hanson Pharmaceutical (03692.HK) announced that the Class 1 new drug HS-10504 tablets independently developed by the company's subsidiary Jiangsu Hausen Pharmaceutical Group Co., Ltd. and Shanghai Hanson Biomedical Technology Co., Ltd. have obtained a clinical trial notice approved and issued by the China National Drug Administration to treat advanced non-small cell lung cancer. The specific indications are to be determined after clinical trials.
Hansoh Pharmaceutical Group Company Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Investors in Hansoh Pharmaceutical Group Company Limited (HKG:3692) had a good week, as its shares rose 4.2% to close at HK$15.48 following the release of its yearly results. It looks like a cre
Citibank: Maintaining Hanson Pharmaceuticals (03692)'s “Buy” Rating and Raising the Target Price to HK$28
Citigroup said it raised Hanson Pharmaceuticals (03692)'s revenue forecasts for this year and next year by 8.6% and 2.7%, respectively, while earnings per share estimates were raised by 29.5% and 15.4%.
Comments
Hansoh Pharmaceutical Group's high P/E ratio may be due to expected earnings recovery. However, with lower than market growth forecast, the high P/E ratio and positive investor sentiment may not be sustainable. Current trading prices may not be reasonable without significant improvement.
Optimistic Investors Push Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Up 28% But Growth Is Lacking 1
Hansoh Pharmaceutical Group's strong financials and moderate growth over the past five years, along with its high rate of profit reinvestment, could potentially boost its stock value in the long-term. Analysts anticipate future earnings momentum.
EV maker $BYD COMPANY(01211.HK$ fell 0.9% at $193.6. $XPENG-W(09868.HK$ lifted 0.6%. Pharmaceuticals $HANSOH PHARMA(03692.HK$ and $TRAD CHI MED(00570.HK$ rebounded to open 4.9% and 2.3% higher. Handset component maker $SUNNY OPTICAL(02382.HK$ and PC maker $LENOVO GROUP(00992.HK$ sank 1.4% and 1.3%.
As for financials, $HSBC HOLDINGS(00005.HK$ opened flat at $57.95. $HKEX(00388.HK$ lost 0.5% at $231.4. $AIA(01299.HK$ shed 1.6% at $58.65. Chinese prope...
As for financials, $HSBC HOLDINGS(00005.HK$ opened flat at $57.95. $HKEX(00388.HK$ lost 0.5% at $231.4. $AIA(01299.HK$ shed 1.6% at $58.65. Chinese prope...
4
HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off
$Hang Seng Index(800000.HK$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN(09995.HK$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK$ ...
Pharmaceuticals were sold off. $REMEGEN(09995.HK$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK$ ...
1
Despite Hansoh Pharmaceutical's high P/E ratio, its minimal earnings growth and slower future growth vs. the market make its valuation questionable. Shareholders and investors may face disappointment as the high P/E isn't justified by the growth outlook.
Read more
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
%Chg